Reuters logo
BRIEF-Indivior says submitted NDA to FDA for schizophrenia​ treatment
October 2, 2017 / 6:34 AM / 21 days ago

BRIEF-Indivior says submitted NDA to FDA for schizophrenia​ treatment

Oct 2 (Reuters) - Indivior Plc:

* U.S. UNIT SUBMITTED NDA TO FDA ON SEPT. 28, TO SEEK MARKETING APPROVAL FOR RBP-7000, INDIVIOR‘S TREATMENT OF SCHIZOPHRENIA​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below